Pharmacotherapy of Chronic and Acute Thyroid Disorders

Through the use of case studies, this session will provide endocrinology expert tips on how to detect, diagnose, and treat the second most common endocrine disorder…thyroid disease. The focus will be on how to manipulate various thyroid hormone replacement drugs as well as antithyroid medications in both clinical and urgent situations.

Credits: 1.50 contact hours; 1.25 are pharmacology
Release Date: March 1, 2021

$37.50

LEARNING OBJECTIVES

As a result of this activity, you will be able to:

1. Relate the effects of thyroid hormone and the H-P-T axis on the presentation and laboratory diagnosis of hyper- and hypothyroid states.
2. Develop treatment strategies and pharmacologic interventions for hyper- & hypothyroidism and postpartum thyroiditis.
3. Identify early signs of impending thyroid emergencies and priority interventions.

CE INFORMATION

Obtain Your Credits

To earn credits for this activity, you must complete all course components in the following order: 1) complete a three-question pre-test; 2) watch the course presentation video; 3) complete the course evaluation; 4) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile dashboard transcript for future access.

Designation Statement

NPACE designates this educational activity for a maximum of 1.50 contact hours, of which 1.25 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.

Accreditation Statement

Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.

DISCLOSURES

Faculty

Contributing faculty, Christine Kessler, MN, ANP, CNS, BC-ADM, CDTC, FAANP, have disclosed the following relevant financial relationships Speaker's Bureau for Novo Nordisk and Salix Pharmaceuticals. 

Planners

All planners and contributors involved in this educational activity have disclosed no relevant financial relationships. 

Disclaimer

The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.

Disclosure of Unlabeled Use

This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

There is no commercial support for this activity.